vs

Side-by-side financial comparison of INVO Fertility, Inc. (IVF) and Nano Labs Ltd (NA). Click either name above to swap in a different company.

Nano Labs Ltd is the larger business by last-quarter revenue ($2.7M vs $1.8M, roughly 1.5× INVO Fertility, Inc.). Nano Labs Ltd runs the higher net margin — 754.5% vs -150.5%, a 905.0% gap on every dollar of revenue. INVO Fertility, Inc. produced more free cash flow last quarter ($-1.8M vs $-8.4M).

INVO Fertility, Inc. is a specialized healthcare company focused on delivering accessible assisted reproductive technology solutions. It develops, manufactures and markets the patented INVOcell intravaginal culture system for in vitro fertilization procedures, serving fertility clinics and patients across North America, Europe and other global regions, with a mission to reduce barriers to high-quality fertility care.

Weebit Nano is a public semiconductor IP company founded in Israel in 2015 and headquartered in Hod HaSharon, Israel. The company develops Resistive Random-Access Memory technologies. Resistive Random-Access Memory is a specialized form of non-volatile memory (NVM) for the semiconductor industry. The company's products are targeted at a broad range of NVM markets where persistence, performance, and endurance are all required. ReRAM technology can be integrated in electronic devices like weara...

IVF vs NA — Head-to-Head

Bigger by revenue
NA
NA
1.5× larger
NA
$2.7M
$1.8M
IVF
Higher net margin
NA
NA
905.0% more per $
NA
754.5%
-150.5%
IVF
More free cash flow
IVF
IVF
$6.6M more FCF
IVF
$-1.8M
$-8.4M
NA

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
IVF
IVF
NA
NA
Revenue
$1.8M
$2.7M
Net Profit
$-2.6M
$20.3M
Gross Margin
Operating Margin
-93.1%
Net Margin
-150.5%
754.5%
Revenue YoY
22.6%
Net Profit YoY
-62.2%
EPS (diluted)
$-0.77
$1.03

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IVF
IVF
NA
NA
Q4 25
$2.7M
Q3 25
$1.8M
Q2 25
$1.9M
$1.2M
Q1 25
$1.6M
Q4 24
$1.7M
Q3 24
$1.4M
Q2 24
$1.8M
$3.5M
Q1 24
$1.6M
Net Profit
IVF
IVF
NA
NA
Q4 25
$20.3M
Q3 25
$-2.6M
Q2 25
$-5.3M
$-985.5K
Q1 25
$-17.4M
Q4 24
$-3.6M
Q3 24
$-1.6M
Q2 24
$-2.2M
$-8.0M
Q1 24
$-1.6M
Gross Margin
IVF
IVF
NA
NA
Q4 25
Q3 25
Q2 25
Q1 25
35.2%
Q4 24
41.4%
Q3 24
31.0%
Q2 24
53.1%
0.1%
Q1 24
45.3%
Operating Margin
IVF
IVF
NA
NA
Q4 25
Q3 25
-93.1%
Q2 25
-160.4%
-459.2%
Q1 25
-1042.1%
Q4 24
-202.0%
Q3 24
-90.7%
Q2 24
-100.9%
-237.2%
Q1 24
-95.7%
Net Margin
IVF
IVF
NA
NA
Q4 25
754.5%
Q3 25
-150.5%
Q2 25
-283.6%
-85.2%
Q1 25
-1060.1%
Q4 24
-211.3%
Q3 24
-113.8%
Q2 24
-122.2%
-231.3%
Q1 24
-101.3%
EPS (diluted)
IVF
IVF
NA
NA
Q4 25
$1.03
Q3 25
$-0.77
Q2 25
$-13.30
$-0.06
Q1 25
$-12.53
Q4 24
$14.86
Q3 24
$-15.11
Q2 24
$-22.39
$-0.12
Q1 24
$-7.55

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IVF
IVF
NA
NA
Cash + ST InvestmentsLiquidity on hand
$4.9M
Total DebtLower is stronger
$2.0M
$24.5M
Stockholders' EquityBook value
$5.8M
$106.5M
Total Assets
$18.8M
$159.3M
Debt / EquityLower = less leverage
0.34×
0.23×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IVF
IVF
NA
NA
Q4 25
$4.9M
Q3 25
Q2 25
$50.8M
Q1 25
Q4 24
Q3 24
Q2 24
$3.3M
Q1 24
Total Debt
IVF
IVF
NA
NA
Q4 25
$24.5M
Q3 25
$2.0M
Q2 25
$4.8M
$24.8M
Q1 25
Q4 24
$7.5M
Q3 24
Q2 24
$22.5M
Q1 24
Stockholders' Equity
IVF
IVF
NA
NA
Q4 25
$106.5M
Q3 25
$5.8M
Q2 25
$2.6M
$86.8M
Q1 25
$3.3M
Q4 24
$12.7M
Q3 24
$-23.3K
Q2 24
$1.4M
$-5.1M
Q1 24
$10.2K
Total Assets
IVF
IVF
NA
NA
Q4 25
$159.3M
Q3 25
$18.8M
Q2 25
$19.3M
$206.4M
Q1 25
$31.7M
Q4 24
$46.4M
Q3 24
$17.0M
Q2 24
$17.8M
$51.2M
Q1 24
$17.3M
Debt / Equity
IVF
IVF
NA
NA
Q4 25
0.23×
Q3 25
0.34×
Q2 25
1.83×
0.29×
Q1 25
Q4 24
0.59×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IVF
IVF
NA
NA
Operating Cash FlowLast quarter
$-1.8M
$-8.3M
Free Cash FlowOCF − Capex
$-1.8M
$-8.4M
FCF MarginFCF / Revenue
-101.6%
-312.3%
Capex IntensityCapex / Revenue
0.5%
2.9%
Cash ConversionOCF / Net Profit
-0.41×
TTM Free Cash FlowTrailing 4 quarters
$-7.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IVF
IVF
NA
NA
Q4 25
$-8.3M
Q3 25
$-1.8M
Q2 25
$-1.7M
$-7.1M
Q1 25
$-3.5M
Q4 24
$-617.4K
Q3 24
$-640.8K
Q2 24
$-1.5M
$-10.8M
Q1 24
$-260.6K
Free Cash Flow
IVF
IVF
NA
NA
Q4 25
$-8.4M
Q3 25
$-1.8M
Q2 25
$-1.7M
$-7.2M
Q1 25
$-3.6M
Q4 24
$-696.3K
Q3 24
Q2 24
$-1.5M
$-15.4M
Q1 24
$-310.3K
FCF Margin
IVF
IVF
NA
NA
Q4 25
-312.3%
Q3 25
-101.6%
Q2 25
-92.6%
-620.3%
Q1 25
-216.9%
Q4 24
-40.6%
Q3 24
Q2 24
-82.3%
-443.4%
Q1 24
-19.7%
Capex Intensity
IVF
IVF
NA
NA
Q4 25
2.9%
Q3 25
0.5%
Q2 25
0.5%
7.2%
Q1 25
0.9%
Q4 24
4.6%
Q3 24
0.0%
Q2 24
3.0%
133.1%
Q1 24
3.2%
Cash Conversion
IVF
IVF
NA
NA
Q4 25
-0.41×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons